[Image from West Pharmaceutical Services]West Pharmaceutical Services (NYSE:WST) announced the recent unveiling of its Daikyo Crystal Zenith needle syringe system.

Exton, Pennsylvania–based West designed the Daikyo Crystal Zenith 2.25mL insert needle syringe system as a technologically advanced cyclic olefin polymer containment and delivery system. It’s meant to offer an alternative to glass, mitigating the risk of breakage and reducing the chance of particulates, contamination and extractables.

The platform expands upon the 1mL insert needle syringe system, allowing for larger volume injections. According to a news release, as market traction on larger dose injections grows, the new CZ syringe system size will help pharmaceutical companies to bring their product to patients in a safe and most user-centric model possible.

West partnered with Daikyo in an exclusive distributor arrangement to provide the CZ Insert Needle Syringe Systems syringe globally.

“By creating a larger fill volume in our high-quality CZ insert needle syringe system, we’re able to answer the needs of more patients with a safe and reliable containment solution,” West VP and GM of Biologics Li Chen said in the release. “Where patients previously may have needed multiple injections to achieve their dose, the 2.25mL insert needle syringe system will allow for fewer or less frequent injections enabling an easier patient experience.”

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceuticals Tagged With: West Pharmaceutical, West Pharmaceutical Services

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.